Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Approps Bill Includes Cancer Screening, Flu Provisions

This article was originally published in The Gray Sheet

Executive Summary

In addition to FDA, funding to other Department of Health and Human Services agencies would be impacted by a hold up in the appropriations process. A $154.9 billion Labor, Health and Human Services, Education, and Related Agencies funding bill made its way through the Senate Appropriations Committee late last month, despite the standstill in the House. The legislation contains a few provisions relevant to the device industry, including about $38 million designated for colorectal cancer prevention efforts, $25 million of which would go to establish a national surveillance campaign to support screening efforts. It also calls for more federal funding of research and development of imaging technologies to detect and treat prostate cancer. Further, it targets $507 million for the development and purchase of vaccines, drugs, medical supplies and diagnostics for pandemic flu.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT026295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel